Global mRNA Vaccines for Animals Market Strategic Research Report

Scope of the Report

The global mRNA Vaccines for Animals market size is predicted to grow from US$ 148 million in 2025 to US$ 3,799 million in 2032; it is expected to grow at a CAGR of 59.7% from 2026 to 2032.

mRNA vaccines for animals are a type of veterinary vaccine that use messenger RNA (mRNA) technology to stimulate an immune response against specific pathogens in livestock, pets, and other animals. These vaccines work by delivering synthetic mRNA encoding viral or bacterial antigens into the animal’s cells, prompting the immune system to recognize and fight the targeted disease. Compared to traditional vaccines, mRNA vaccines offer faster development timelines, improved efficacy, and the ability to rapidly adapt to emerging animal diseases. They are being explored for various applications, including livestock diseases (such as foot-and-mouth disease), zoonotic infections, and companion animal health.

Market Development Opportunities & Main Driving Factors

mRNA vaccines for animals, as a new generation of biological products, are reshaping the global veterinary vaccine landscape with their rapid development, high specificity, and scalability. According to annual reports from animal health companies and brokerage research, the demand for epidemic prevention in the livestock industry continues to rise, particularly against transboundary infectious diseases and major animal epidemics, which accelerates investment in novel vaccines. The proven success of mRNA technology in human COVID-19 vaccines validates its potential in veterinary applications. Coupled with strong policy support for food safety, livestock modernization, and public health, the market expansion potential for animal mRNA vaccines is significant.

Market Challenges, Risks, & Restraints

Despite promising prospects, animal mRNA vaccines face multiple challenges. Their storage, transportation, and mass production require stringent cold chain and advanced equipment, leading to higher costs compared to traditional vaccines. Regulatory frameworks remain immature, with varying standards for registration and safety validation across regions, adding uncertainty to commercialization. Additionally, the industry is dominated by multinational animal health giants with strong technological and financial advantages, creating barriers for smaller firms facing fierce competition and potential technological hurdles.

Downstream Demand Trends

As livestock farming becomes increasingly large-scale and intensive, and as consumer awareness of food safety and animal health grows, demand for safe and effective novel vaccines continues to rise. In particular, poultry, swine, and companion animal sectors exhibit strong demand for rapid-response vaccines against emerging diseases. Growing government investment in animal disease prevention and farmers’ need to reduce losses and improve efficiency will further drive adoption. In the long term, animal mRNA vaccines are poised to become a critical technology supporting livestock stability and food supply security.

This report presents a comprehensive overview of the global mRNA Vaccines for Animals market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Non-replicating mRNA vaccines
• Self-replicating mRNA vaccines

Segment by players, this report covers

• Ceva Animal Health
• Merck Animal Health
• Areterna
• Bayer
• BioNTech
• Genvax Technologies
• BioVenic
• Moderna
• Ruipu Biotechnology
• Jinyu Bio-technology
• Shanghai Shen Lian Biomedical
• Suzhou Kerui Meide Biomedical Technology
• Shanghai Rnacure Biopharma

Segment by Application

• Pigs
• Poultry
• Companion Animals
• Ruminants

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global mRNA Vaccines for Animals market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Pigs, Poultry, Companion Animals evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact